Recently, advances in wearable technologies, data science and machine learning have
begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …

Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …